

Sent: 06 November 2006 13:00

To: Christopher Feinmann

Subject: Comments on the Evaluation Report-Fludarabine

I have the following comments on the Evaluation Report on Fludarabine which ,as requested, are submitted seperately:-

1 Page 1 Erratum

I am puzzled by the statement at the end of the revised Para 2.3.4 that now states that:-

'First line treatment with fludarabine plus cyclophosphamide alone is ,however,associated with increased toxicity,inconvenience,expense and impaired quality of life because two courses of chemotherapy are needed'

I cannot find this statement in any of the Clinical expert submissions and I would ask what is the evidence base for this statement?

2 Evidence Review Group Report

There is an error on page 14 Section 2.1.4 Treatment.

Second line from the bottom should read ' fludarabine in combination with either cyclophosphamide or cyclophosphamide plus rituximab'

The reference to chlorambucil is wrong.As noted on page 8 of the ERG report fludarabine plus chlorambucil shows excessive toxicity.

This error could potentially mislead members of the evaluation committee.

Regards

UK Registered Charity No. 1113588

Registered address:-

4,Deansfield,Winchester Hill,Romsey,Hants,England

SO51 7NE

www.cllsupport.org.uk

' Together fighting Chronic Lymphocytic Leukaemia'

Delivered via MessageLabs
